LYEL (Lyell Immunopharma, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by LYEL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | Veronica Sanchez Bulis | VP, Corporate Controller | Sell | — | — |
| 2026-08-11 | Lynn Seely | President and CEO | Sell | — | — |
| 2026-08-11 | Gary K. Lee | Chief Scientific Officer | Sell | — | — |
| 2026-08-11 | Stephen J. Hill | Chief Operating Officer | Sell | — | — |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | J | — | — |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | J | — | — |
| 2026-07-20 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | Sell | — | — |
| 2026-07-17 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | Sell | — | — |
| 2026-07-01 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | J | — | — |
| 2026-06-18 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | J | — | — |
| 2026-06-15 | Lynn Seely | President and CEO | Sell | — | — |
| 2026-06-15 | Stephen J. Hill | Chief Operating Officer | Sell | — | — |
| 2026-06-15 | Veronica Sanchez Bulis | VP, Corporate Controller | Sell | — | — |
| 2026-06-15 | Gary K. Lee | Chief Scientific Officer | Sell | — | — |
| 2026-06-12 | Mark Bachleda | Director | A | — | — |
| 2026-06-12 | Richard Klausner | Director | A | — | — |
| 2026-06-12 | OTIS W BRAWLEY | Director | A | — | — |
| 2026-06-12 | ELIZABETH G NABEL | Director | A | — | — |
| 2026-06-12 | CATHY FRIEDMAN | Director | A | — | — |
| 2026-06-12 | WILLIAM JL RIEFLIN | Director | A | — | — |
| 2026-06-12 | Sumant Ramachandra | Director | A | — | — |
| 2026-06-11 | David Shook | Chief Medical Officer | Sell | — | — |
| 2026-03-16 | Smital Shah | Chief Fin. and Bus. Officer | A | — | — |
| 2026-03-09 | PAUL L BERNS | 10%+ Owner | Buy | — | — |
| 2026-03-09 | ARCH Venture Partners IX, LLC | 10%+ Owner | Buy | — | — |
| 2026-02-12 | Gary K. Lee | Chief Scientific Officer | Sell | — | — |
| 2026-02-12 | Stephen J. Hill | Chief Operating Officer | Sell | — | — |
| 2026-02-12 | Lynn Seely | President and CEO | Sell | — | — |
| 2026-02-11 | Mark A Meltz | General Counsel | A | — | — |
| 2026-02-11 | Veronica Sanchez Bulis | VP, Corporate Controller | MIXED | — | — |
| 2026-02-11 | Lynn Seely | President and CEO | MIXED | — | — |
| 2026-02-11 | Stephen J. Hill | Chief Operating Officer | MIXED | — | — |
| 2026-02-11 | Gary K. Lee | Chief Scientific Officer | MIXED | — | — |
| 2026-02-11 | David Shook | Chief Medical Officer | A | — | — |
| 2026-01-06 | Veronica Sanchez Bulis | VP, Corporate Controller | Sell | — | — |
| 2025-11-12 | Stephen J. Hill | Chief Operating Officer | Sell | — | — |
| 2025-11-12 | Veronica Sanchez Bulis | VP, Corporate Controller | Sell | — | — |
| 2025-11-12 | Lynn Seely | President and CEO | Sell | — | — |
| 2025-11-12 | Gary K. Lee | Chief Scientific Officer | Sell | — | — |
| 2025-10-29 | Lynn Seely | President and CEO | A | — | — |
| 2025-10-29 | Gary K. Lee | Chief Scientific Officer | A | — | — |
| 2025-10-29 | Stephen J. Hill | Chief Operating Officer | A | — | — |
| 2025-08-22 | Charles W. Newton | Chief Financial Officer | MIXED | — | — |
| 2025-08-22 | Lynn Seely | President and CEO | MIXED | — | — |
| 2025-08-22 | Gary K. Lee | Chief Scientific Officer | MIXED | — | — |
| 2025-08-22 | Stephen J. Hill | Chief Operating Officer | MIXED | — | — |
| 2025-08-13 | Stephen J. Hill | Chief Operating Officer | Sell | — | — |
| 2025-08-13 | Lynn Seely | President and CEO | Sell | — | — |
| 2025-08-13 | Gary K. Lee | Chief Scientific Officer | Sell | — | — |
| 2025-08-13 | Charles W. Newton | Chief Financial Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,774,980 | — |
| — | 10%+ Owner | 1,512,659 | — |
| — | Director | 910,318 | — |
| — | 10%+ Owner | 910,318 | — |
| — | 10%+ Owner | 910,317 | — |
| — | 10%+ Owner | 910,317 | — |
| — | 10%+ Owner | 910,317 | — |
| — | Director | 234,281 | — |
| — | Director | 190,557 | — |
| — | President and CEO | 73,488 | — |
| — | Chief Financial Officer | 25,306 | — |
| — | Chief Medical Officer | 20,923 | — |
| — | Chief Operating Officer | 17,805 | — |
| — | Chief Scientific Officer | 17,677 | — |
| — | VP, Corporate Controller | 14,799 | — |
| — | Director | 10,000 | — |
| — | Chief Business Officer | 8,125 | — |
| — | Director | 5,000 | — |
| — | Director | 1,782 | — |
| — | Chief Medical Officer | 202 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LYEL quote page; the site-wide leaderboard is on the insider transactions hub.